Healio reports that the FDA has expanded Deep TMS’s indication for treating depression in older adults, recognizing its efficacy and safety. This approval extends to individuals aged 68 to 86, acknowledging Deep TMS’s benefits in addressing late-life depression. The decision follows a pivotal study demonstrating Deep TMS’s effectiveness in this population, with significant improvements in depressive symptoms. The expanded indication marks a significant milestone in mental health treatment for older adults, offering a noninvasive and well-tolerated option for managing depression. This decision underscores the importance of innovative therapies like Deep TMS in addressing the unique needs of elderly patients battling depression.
